Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 22:e2515185.
doi: 10.1001/jama.2025.15185. Online ahead of print.

Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial

Collaborators, Affiliations

Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial

Stefan T Engelter et al. JAMA. .

Abstract

Importance: Levodopa enhances dopaminergic signaling and may stimulate neuroplasticity, which could potentially enhance motor recovery after stroke. Levodopa is used in stroke rehabilitation despite mixed evidence for its effectiveness.

Objective: To determine whether levodopa compared with placebo, administered in addition to standardized rehabilitation based on active task-oriented training, is associated with enhanced motor recovery in patients with acute stroke.

Design, setting, and participants: A double-blind, placebo-controlled randomized clinical trial at 13 stroke units and centers and 11 collaborating rehabilitation centers in Switzerland. Between June 14, 2019 (first patient, first visit), and August 27, 2024 (last patient, last visit), 610 patients with acute ischemic or hemorrhagic stroke with clinically meaningful hemiparesis (ie, a total score of ≥3 points on the following National Institutes of Health Stroke Scale items: motor arm, motor leg, or limb ataxia) were randomized 1:1 to receive levodopa or placebo. Statistical analyses were conducted from November 2024 to August 2025.

Intervention: Patients received levodopa/carbidopa (100 mg/25 mg; n = 307) or placebo (n = 303) 3 times daily for 39 days, alongside standardized rehabilitation therapy based on active task-oriented training.

Main outcomes and measures: The primary outcome was the adjusted mean between-group difference in the Fugl-Meyer Assessment (FMA) total score (range, 0-100 points; fewer points indicate worse motor function; 6-point difference considered patient-relevant) at 3 months.

Results: Among the 610 participants (median [IQR] age, 73 [64-82] years; 252 [41.3%] female; median baseline FMA total score, 34 [14-54]), 28 participants died by 3 months, leaving 582 (95.4%) participants eligible for the primary analysis. At 3 months, the median (IQR) FMA total score was 68 (42-85) points in the levodopa group and 64 (44-83) points in the placebo group. The mean difference in the FMA total score between the levodopa and placebo groups was -0.90 points (95% CI, -3.78 to 1.98; P = .54). There were 126 serious adverse events in the levodopa group and 129 in the placebo group; the most common was infection (levodopa, n = 55; placebo, n = 44).

Conclusions and relevance: In this randomized clinical trial, among patients receiving inpatient rehabilitation for acute stroke, levodopa added to standardized rehabilitation did not significantly improve motor function at 3 months compared with placebo plus standardized rehabilitation. These results do not support the use of levodopa as an adjunct to rehabilitation therapy for enhancing motor recovery after acute stroke.

Trial registration: ClinicalTrials.gov Identifier: NCT03735901.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Engelter reported receiving an investigator-initiated research grant to their institution from Swiss National Science Foundation (SNSF) during the conduct of the study. Ms Wiegert reported receiving grants from SNSF during the conduct of the study. Dr Greulich reported receiving personal fees from Novartis, Pfizer AG, and Lundbeck AG outside the submitted work. Dr Katan reported receiving grants from SNSF and Swiss Heart Foundation; and personal fees for serving on the advisory boards of Bristol Myers Squibb, Janssen, AstraZeneca, and Medtronic outside the submitted work. Dr Fischer reported receiving consulting fees to their institution from AbbVie, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, CSL, and Siemens outside the submitted work; and being the president of the European Stroke Organization, president-elect of Swiss Federation of Clinical Neuro-Societies, and president of the Advanced Training in Neuro-subjects task force at Swiss Neurological Society. Dr Seiffge reported receiving consulting and advisory fees paid to their institution from AstraZeneca; and grants from Swiss Heart Foundation, SNSF, and AstraZeneca outside the submitted work. Dr Bonati reported receiving grants from SNSF outside the submitted work. Dr Humm reported receiving reimbursement from University of Basel for patient recruitment and follow-up during the conduct of the study. Dr Sandor reported serving as a board member of Swiss Neurological Society, Swiss Society for Neurorehabilitation, and SW!SS REHA. Dr Michel reported receiving grants from SNSF, Swiss Heart Foundation, Faculty of Biology and Medicine of the University of Lausanne, and Porphyrogenis Foundation outside the submitted work. Dr Hemkens reported receiving grants from SNSF (179667) during the conduct of the study; working for Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel and University Hospital Basel, which is supported by Foundation of Clinical Neuroimmunology and Neuroscience Basel; and RC2NB having a contract with Roche for Dr Hemkens’ steering committee participation outside the submitted work. Dr Gensicke reported receiving grants from SNSF during the conduct of the study; grants from AbbVie, Merz, and Ipsen; and personal fees from AbbVie outside the submitted work. Dr Traenka reported receiving grants from Swiss Heart Foundation; honoraria from Reha Rheinfelden for lectures during the conduct of the study; and grants from Swiss Heart Foundation outside the submitted work. No other disclosures were reported.

References

    1. Grefkes C, Fink GR. Recovery from stroke: current concepts and future perspectives. Neurol Res Pract. 2020;2:17. doi: 10.1186/s42466-020-00060-6 - DOI - PMC - PubMed
    1. Winstein CJ, Stein J, Arena R, et al. ; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research . Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(6):e98-e169. doi: 10.1161/STR.0000000000000098 - DOI - PubMed
    1. Cramer SC. Drugs to enhance motor recovery after stroke. Stroke. 2015;46(10):2998-3005. doi: 10.1161/STROKEAHA.115.007433 - DOI - PMC - PubMed
    1. Kumar A, Kitago T. Pharmacological enhancement of stroke recovery. Curr Neurol Neurosci Rep. 2019;19(7):43. doi: 10.1007/s11910-019-0959-2 - DOI - PubMed
    1. Keser Z, Francisco GE. Neuropharmacology of poststroke motor and speech recovery. Phys Med Rehabil Clin N Am. 2015;26(4):671-689. doi: 10.1016/j.pmr.2015.06.009 - DOI - PubMed

Associated data